A new Beginning..., page-3011

TK has a large presentation on next week in Boston: https://www.resapphealth.com.au/investor-relations/events-and-presentations/

He then has the Techknow presentation the week after.

I'd expect an updated power point presentation to be released next week for these presentations.


By the way, the chronic / management of illness results (yellow) have not been released yet. Its expected Q4 19.
IMO the market hasn't factored this potential of the management of illness capability into the share price, and this component of Resapp's capabilities doesn't get discussed often on HC.

If these trial results are positive (POC results were great) it will enable Resapp algorithms to quantify the level of severity of respiratory illnesses in addition to diagnosing. The way I understand - one example of this potential could be that if your child has asthma you could monitor their level of asthma via a smartphone while they are at school. If the app showed a 1 out of 4 it could mean no action required, 2 or 3 out of 4 may mean increase asthma inhalation, monitor and reduce exercise,  and then a 4/4 could mean they need hospitalisation as an asthma attack is imminent.
Similar for COPD. FYI - there are 24m people living with COPD just in USA. In China as a result of sever pollution and  smoking rates the number of COPD sufferers is at epidemic levels. Imo this is what Ping An, WeDoctor and Alibaba Health would be most interested in.